AUTHOR=Rezaee Malihe , Mohammadi Fatemeh , Keshavarzmotamed Atoosa , Yahyazadeh Sheida , Vakili Omid , Milasi Yaser Eshaghi , Veisi Vida , Dehmordi Rohollah Mousavi , Asadi Sepideh , Ghorbanhosseini Seyedeh Sara , Rostami Mehdi , Alimohammadi Mina , Azadi Abbas , Moussavi Nushin , Asemi Zatollah , Aminianfar Azadeh , Mirzaei Hamed , Mafi Alireza TITLE=The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1152672 DOI=10.3389/fphar.2023.1152672 ISSN=1663-9812 ABSTRACT=

Breast cancer (BC) is the most common malignancy among women worldwide. Like many other cancers, BC therapy is challenging and sometimes frustrating. In spite of the various therapeutic modalities applied to treat the cancer, drug resistance, also known as, chemoresistance, is very common in almost all BCs. Undesirably, a breast tumor might be resistant to different curative approaches (e.g., chemo- and immunotherapy) at the same period of time. Exosomes, as double membrane-bound extracellular vesicles 1) secreted from different cell species, can considerably transfer cell products and components through the bloodstream. In this context, non-coding RNAs (ncRNAs), including miRNAs, long ncRNAs (lncRNAs), and circular RNAs (circRNAs), are a chief group of exosomal constituents with amazing abilities to regulate the underlying pathogenic mechanisms of BC, such as cell proliferation, angiogenesis, invasion, metastasis, migration, and particularly drug resistance. Thereby, exosomal ncRNAs can be considered potential mediators of BC progression and drug resistance. Moreover, as the corresponding exosomal ncRNAs circulate in the bloodstream and are found in different body fluids, they can serve as foremost prognostic/diagnostic biomarkers. The current study aims to comprehensively review the most recent findings on BC-related molecular mechanisms and signaling pathways affected by exosomal miRNAs, lncRNAs, and circRNAs, with a focus on drug resistance. Also, the potential of the same exosomal ncRNAs in the diagnosis and prognosis of BC will be discussed in detail.